$33.92 -0.04 (%) NPS Pharmaceuticals Inc - NASDAQ

Nov. 28, 2014 | 12:20 PM

Partner Headlines

  1. Morning Market Losers

    Benzinga | Oct. 24, 2014 | 09:54AM EST
  2. Benzinga's Top #PreMarket Losers

    Benzinga | Oct. 24, 2014 | 08:18AM EST
  3. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga | Oct. 20, 2014 | 16:58PM EST
  4. Benzinga's Weekend M&A Chatter

    Benzinga | Oct. 19, 2014 | 21:58PM EST
  5. Technology Stocks Down As Rest Of The Market Starts Week Flat

    Benzinga | Sep. 15, 2014 | 17:15PM EST
  6. Terex Falls After Lowered Earnings Forecast; Avanir Pharmaceuticals Shares Surge

    Benzinga | Sep. 15, 2014 | 15:40PM EST
  7. NASDAQ Tumbles 1.1%; Alere Shares Surge Following Proposed $46/Share Offer

    Benzinga | Sep. 15, 2014 | 13:24PM EST
  8. Markets Fall; Cognizant To Acquire TriZetto For $2.7 Billion

    Benzinga | Sep. 15, 2014 | 11:26AM EST
  9. Morning Market Losers

    Benzinga | Sep. 15, 2014 | 09:48AM EST
  10. Benzinga's Top #PreMarket Losers

    Benzinga | Sep. 15, 2014 | 08:15AM EST
  11. US Stock Futures Flat Ahead Of Economic Data

    Benzinga | Sep. 12, 2014 | 07:40AM EST
  12. NPS Pharma Stock Trading Halted Today; FDA Advisory Committee to Review Natpara Biologics License Application

    Benzinga | Sep. 12, 2014 | 07:07AM EST
  13. FDA says NPS drug is effective

    IBD | Sep. 10, 2014 | 18:53PM EST
  14. Stocks Gain As Oil, Euro Continue Sharp Sell Off

    Benzinga | Sep. 10, 2014 | 17:09PM EST
  15. Lands' End Jumps On Strong Quarterly Earnings; GT Advanced Technologies Shares Slide

    Benzinga | Sep. 10, 2014 | 15:29PM EST
  16. U.S. Stocks Rise; Palo Alto Networks Shares Surge On Upbeat Revenue

    Benzinga | Sep. 10, 2014 | 12:48PM EST
  17. Markets Edge Lower; Krispy Kreme Doughnuts Profit Misses Estimates

    Benzinga | Sep. 10, 2014 | 11:22AM EST
  18. Benzinga's Volume Movers

    Benzinga | Sep. 10, 2014 | 10:20AM EST
  19. Morning Market Movers

    Benzinga | Sep. 10, 2014 | 09:39AM EST
  20. FDA Posts Briefing Materials For Advisory Committee Meeting Reviewing Natpara For Hypoparathyroidism

    Benzinga | Sep. 10, 2014 | 08:07AM EST
  21. NPS Pharma Initiates Phase 2a Study Of NPSP795 In Adult Patients With Autosomal Dominant Hypocalcemia (ADH)

    Benzinga | Aug. 4, 2014 | 08:13AM EST
  22. Valeant Goes For Allergan; Analyst Touts Shire Option

    IBD | Jun. 18, 2014 | 11:57AM EST
  23. Mid-Afternoon Market Update: Markets Turn Back As SolarCity Hangs Onto Gains

    Benzinga | May. 8, 2014 | 15:36PM EST
  24. Mid-Day Market Update: Keurig Green Mountain Jumps On Upbeat Earnings; Tesla Shares Slide

    Benzinga | May. 8, 2014 | 13:11PM EST
  25. Mid-Morning Market Update: Markets Gain; Wendy's Profit Beats Street View

    Benzinga | May. 8, 2014 | 10:47AM EST
  26. Morning Market Losers

    Benzinga | May. 8, 2014 | 09:51AM EST
  27. UPDATE: Canaccord Genuity Assumes Coverage on NPS Pharmaceuticals on Recent Market Weakness

    Benzinga | Apr. 16, 2014 | 09:46AM EST
  28. Benzinga's Top Initiations

    Benzinga | Mar. 25, 2014 | 08:26AM EST
  29. UPDATE: Jefferies Downgrades NPS Pharmaceuticals on Valuation

    Benzinga | Feb. 19, 2014 | 10:30AM EST
  30. NPS Pharma Finds Big Success In Tiny Markets

    IBD | Feb. 13, 2014 | 18:15PM EST
  31. Market Wrap For January 8: Fed Minutes Released

    Benzinga | Jan. 8, 2014 | 16:39PM EST
  32. NPS Pharmaceuticals Receives Orphan Drug Designation for Natpara by EC

    Benzinga | Jan. 3, 2014 | 08:34AM EST
  33. Catalyst Stock Plunge: Ugly In Orphan Drug Land

    YCharts | Nov. 7, 2013 | 12:54PM EST
  34. Mid-Afternoon Market Update: Markets Mixed as Tesla Shares Remain Down

    Benzinga | Nov. 6, 2013 | 15:41PM EST
  35. NPS Pharma Says Data from STEPS 2 Trial of Gattex Supports Long-Term Use

    Benzinga | Oct. 14, 2013 | 08:04AM EST
  36. Mid-Afternoon Market Update: Markets Green as Spirit Airlines Soars

    Benzinga | Oct. 11, 2013 | 15:57PM EST
  37. Mid-Day Market Update: Micron Shares Tumble On Downbeat Profit; SolarCity Spikes Higher

    Benzinga | Oct. 11, 2013 | 12:39PM EST
  38. Mid-Morning Market Update: Markets Rise; JPMorgan Posts Upbeat Core Earnings

    Benzinga | Oct. 11, 2013 | 10:34AM EST
  39. Orphan Drugs: No (Payer) News Is Good News

    YCharts | Oct. 9, 2013 | 14:08PM EST
  40. NPS Pharma Says 53% of Natpara-Treated Patients Achieved Primary Endpoint

    Benzinga | Oct. 7, 2013 | 08:09AM EST
  41. UPDATE: Bank of America Initiates Coverage on NPS Pharmaceuticals as Gattex and Natpara Could Provide Meaningful Annuities

    Benzinga | Oct. 3, 2013 | 10:17AM EST
  42. Benzinga's Top Initiations

    Benzinga | Oct. 3, 2013 | 07:29AM EST
  43. NPS Pharma Says sNDA Submitted for Gattex STEPS 2 Data, Shows Sustained Effects

    Benzinga | Oct. 2, 2013 | 08:13AM EST
  44. Weekly CFO Sells Highlight: WRES, NPSP, MKTO, GRPN, RXN

    GuruFocus | Sep. 29, 2013 | 14:43PM EST
  45. UPDATE: J.P. Morgan Initiates Coverage on NPS Pharmaceuticals on Emerging Market Leader Status

    Benzinga | Sep. 20, 2013 | 10:39AM EST
  46. Benzinga's Top Initiations

    Benzinga | Sep. 20, 2013 | 07:48AM EST
  47. UPDATE: Oppenheimer Raises PT on NPS Pharmaceuticals Following Gattex Survey

    Benzinga | Aug. 21, 2013 | 12:05PM EST
  48. Market Wrap for Friday, August 9: Stocks Close Lower To End Week

    Benzinga | Aug. 9, 2013 | 16:35PM EST
  49. NPS Pharmaceuticals Chief: Why 250k-a-Year Orphan Drug is Worth It

    YCharts | Feb. 1, 2013 | 06:17AM EST
  50. You Can Expect More Insider Trading in Pharma Stocks: Here's Why

    YCharts | Dec. 28, 2012 | 04:47AM EST
Trading Center